GUD.TO KNIGHT THERAPEUTICS INC
$9.85▲ +1.23%
Healthcare
Other
Volume 197.5K
Avg Volume (10D) 95.2K
Key Metrics & Fundamentals
Market Cap
$967.58M
P/E Ratio
65.7
Div Yield
–%
52W Range
5.66 - 10.17
% vs 50 MA
0.06%
% vs 200 MA
26.33%
RSI-14
50.8
MACD Histogram
+0.0200
Beta (1Y vs SPY)
0.15
Free Cash Flow
$27.92M
Gross Rev
$144.21M
Gross Profit
$69.62M
EBITDA
$24.38M
COGS
$74.60M
Operating Exp
$60.66M
Operating Income
$8.96M
EBIT
$8.96M
Pretax Income
-$2.10M
Net Income
-$3.36M
EPS (Diluted)
-0.03
Price & Volume History
Loading chart…
Recent News
Knight Therapeutics Gets Regulatory Approval for TAVALISSE in Colombia
MT Newswires · Sep 2, 2026 9:37 AM
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia
GlobeNewswire · Sep 1, 2026 10:00 PM
Knight Therapeutics Submits Supplemental Application for MINJUVI in Brazil
MT Newswires · Aug 28, 2026 10:30 AM
Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil
MT Newswires · Aug 28, 2026 10:26 AM
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
GlobeNewswire · Aug 27, 2026 10:00 PM
Knight Therapeutics Price Target Raised to C$11.50 at Raymond James
MT Newswires · Aug 25, 2026 11:34 AM
Knight Therapeutics Launches Psoriasis Treatment Cream, Wynzora, in Canada
MT Newswires · Aug 20, 2026 3:55 PM
Knight Therapeutics Announces Launch of WYNZORA® in Canada
GlobeNewswire · Aug 20, 2026 11:30 AM
TherapeuticsMD Announces Second Quarter 2026 Financial Results
Business Wire · Aug 11, 2026 8:00 PM
Knight Therapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 10, 2026 12:03 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See GUD.TO's money flow as a full page
Social Sentiment
No Reddit posts found for GUD.TO.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.